Literature DB >> 30027786

Respiratory syncytial virus prevents the subsequent development of ovalbumin-induced allergic responses by inhibiting ILC2 via the IL-33/ST2 pathway.

Dandan Wang1,2, Song Bai2, Yulin Cui2, Na Zhao2, Feifei Qi2, Jing Liu2, Sheng Zeng2, Lei Xu2, Haiyan Hu2, Beixing Liu2.   

Abstract

AIM: How respiratory syncytial virus (RSV) influences the development of ovalbumin (OVA)-induced asthma remains elusive. As potent T helper (Th)2 cytokine producers, group 2 innate lymphoid cells (ILC2s) are known to serve important functions in the pathogenesis of allergic inflammation. However, how RSV infection affects innate immunity, especially with regard to the function of ILC2s in OVA-induced allergic airway inflammation, is largely unknown. MATERIALS &
METHODS: RSV was used to infect adult BALB/c mice intranasally prior to sensitization and subsequent challenge with OVA. ILC2 frequencies and Th2 cytokine production by ILC2s were assessed by flow cytometry. Cytokine levels were detected both by real-time PCR and ELISA.
RESULTS: Previous infection with RSV attenuated airway inflammation and decreased Th2 cytokine production in mice sensitized and challenged with OVA. Furthermore, previous infection with RSV inhibited the influx of ILC2s into the lung, and constrained their Th2 cytokine production. Adoptive transfer of ILC2s increased asthma-associated airway inflammation in mice previously infected with RSV. These results indicate that previous infection with RSV prevents OVA-induced asthma development via inhibition of ILC2s. Previous infection with RSV attenuated IL-33 production in lung tissue and reduced relative ST2L expression in lung ILC2s, meaning that previous infection with RSV may alter ILC2 function via the IL-33/ST2 signaling pathway.
CONCLUSION: These results demonstrate that previous infection with RSV attenuates OVA-induced airway inflammation by inhibiting the recruitment and Th2 cytokine production of ILC2s via the IL-33/ST2 pathway.

Entities:  

Keywords:  IL-33/ST2; ILC2; RSV; allergic airway inflammation; group 2 innate lymphoid cell; respiratory syncytial virus

Mesh:

Substances:

Year:  2018        PMID: 30027786     DOI: 10.2217/imt-2018-0059

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  6 in total

1.  Wenshen decoction suppresses inflammation in IL-33-induced asthma murine model via inhibiting ILC2 activation.

Authors:  Weiling Huang; Ying Song; Lixin Wang
Journal:  Ann Transl Med       Date:  2019-10

Review 2.  Small Animal Models of Respiratory Viral Infection Related to Asthma.

Authors:  Mingyuan Han; Charu Rajput; Tomoko Ishikawa; Caitlin R Jarman; Julie Lee; Marc B Hershenson
Journal:  Viruses       Date:  2018-12-01       Impact factor: 5.048

3.  Uric acid pathway activation during respiratory virus infection promotes Th2 immune response via innate cytokine production and ILC2 accumulation.

Authors:  Wendy Fonseca; Carrie-Anne Malinczak; Charles F Schuler; Shannon K K Best; Andrew J Rasky; Susan B Morris; Tracy X Cui; Antonia P Popova; Nicholas W Lukacs
Journal:  Mucosal Immunol       Date:  2020-02-11       Impact factor: 7.313

Review 4.  Innate Type 2 Responses to Respiratory Syncytial Virus Infection.

Authors:  Allison E Norlander; R Stokes Peebles
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

5.  Bronchiolitis and recurrent wheezing are distinguished by type 2 innate lymphoid cells and immune response.

Authors:  Beatriz Sastre; María Luz García-García; José Antonio Cañas; Cristina Calvo; José Manuel Rodrigo-Muñoz; Inmaculada Casas; Ignacio Mahíllo-Fernández; Victoria Del Pozo
Journal:  Pediatr Allergy Immunol       Date:  2020-07-23       Impact factor: 5.464

6.  Oral administration of Clostridium butyricum rescues streptomycin-exacerbated respiratory syncytial virus-induced lung inflammation in mice.

Authors:  Wenwen Zhu; Jia Wang; Na Zhao; Rui Zheng; Dalu Wang; Weiwei Liu; Beixing Liu
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.